Peptipedia
Weight LossPreclinicalAnimal Studies

5-Amino-1MQ

Also known as 5-amino-1-methylquinolinium, NNMT Inhibitor

A selective NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular energy metabolism. Not technically a peptide but a small molecule research compound. Mouse studies showed 30%+ decrease in adipocyte size.

Preclinical Research
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

50-75 mg daily

Frequency

Once daily, morning

Duration

4-6 weeks (cycling: 4-6 weeks on, 2-4 weeks off)

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 50-75 mg daily via Subcutaneous injection or oral, Once daily, morning. Dose range: 50-100 mg daily. Duration: 4-6 weeks (cycling: 4-6 weeks on, 2-4 weeks off).

Timing & Administration

Administer via Subcutaneous injection or oral. Frequency: Once daily, morning.

Mechanism of Action

Inhibits NNMT, an enzyme that regulates NAD+ and SAM (S-adenosyl methionine) levels. Increases NAD+ availability, enhancing mitochondrial function and fat oxidation without affecting appetite.

Research Summary

Evidence level: animal studies. Clinical status: Preclinical Research.

Side Effects & Safety

Important Warnings

  • Only animal studies
  • No human clinical trial data.
Mild headache (initial dosing)
nausea
increased alertness/jitteriness
insomnia (rare)
elevated blood pressure (rare)

References

No references available.

Related Peptides

Browse all →
SemaglutideWeight Loss

A GLP-1 receptor agonist with multiple FDA approvals including weight management, type 2 diabetes treatment, cardiovascular risk reduction, and kidney disease protection. 94% amino acid similarity to human GLP-1.

View profile
TirzepatideWeight Loss

A dual GIP/GLP-1 receptor agonist representing next-generation incretin-based therapy, demonstrating superior weight loss outcomes compared to semaglutide in direct clinical comparisons.

View profile
RetatrutideWeight Loss

A triple agonist activating GLP-1, GIP, and glucagon receptors for enhanced weight loss outcomes.

View profile